ARMATA PHARMACEUTICALS, INC.: Announces Publication of Successful Adjunctive Phage Treatment in Cystic Fibrosis Patient

Armata Pharmaceuticals, Inc. (NYSE American: ARMP), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, announced the publication of a case study involving a cystic fibrosis patient who was successfully treated for a multidrug-resistant Pseudomonas aeruginosa infection with the Company's natural phage product, AP-PA01. Read More »